Maron B.J. Doerer J.J. Haas T.S. et al.

Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006.

Circulation. 119: 1085-1092Corrado D. Basso C. Rizzoli G. et al.

Does sports activity enhance the risk of sudden death in adolescents and young adults?.

J Am Coll Cardiol. 42: 1959-1963Eckart R. Shry E. Burke A. et al.

Department of Defense Cardiovascular Death Registry G. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance.

J Am Coll Cardiol. 58: 5Eckart R.E. Scoville S.L. Campbell C.L. et al.

Sudden death in young adults: a 25-year review of autopsies in military recruits.

Ann Intern Med. 141: 829-834Harmon K.G. Asif I.M. Maleszewski J.J. et al.

Incidence, cause, and comparative frequency of sudden cardiac death in national collegiate athletic association athletes: a decade in review.

Circulation. 132: 10-19Harmon K.G. Asif I.M. Maleszewski J.J. et al.

Incidence and etiology of sudden cardiac arrest and death in high school athletes in the United States.

Mayo Clin Proc. 11th. 91. Elsevier, : 1493-1502https://doi.org/10.1016/j.mayocp.2016.07.021Harmon K.G. Drezner J.A. Maleszewski J.J. et al.

Pathogeneses of sudden cardiac death in national collegiate athletic association athletes.

Circ Arrhythmia Electrophysiol. 7: 198-204Holst A.G. Winkel B.G. Theilade J. et al.

Incidence and etiology of sports-related sudden cardiac death in Denmark—implications for preparticipation screening.

Heart Rhythm. 7: 1365-1371Papadakis M. Sharma S. Cox S. et al.

The magnitude of sudden cardiac death in the young: a death certificate-based review in England and Wales.

Europace. 11: 1353-1358Puranik R. Chow C.K. Duflou J.A. et al.

Sudden death in the young.

Heart rhythm. 2: 1277-1282Solberg E.E. Gjertsen F. Haugstad E. et al.

Sudden death in sports among young adults in Norway.

Eur J Prev Cardiol. 17: 337-341Maron B.J. Thompson P.D. Ackerman M.J. et al.

Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.

Circulation. 115: 1643-1655Peretto G. Sala S. Rizzo S. et al.

Arrhythmias in myocarditis: state of the art.

Heart Rhythm. 16: 793-801Mahrholdt H. Wagner A. Deluigi C.C. et al.

Presentation, patterns of myocardial damage, and clinical course of viral myocarditis.

Circulation. 114: 1581-1590Jain A. Norton N. Bruno K.A. et al.

Sex differences, genetic and environmental influences on dilated cardiomyopathy.

J Clin Med. 10: 2289Kuhl U. Pauschinger M. Noutsias M. et al.

High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction.

Circulation. 111: 887-893Committee W. Gluckman T.J. Bhave N.M. et al.

2022 ACC expert Consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of cardiology solution set oversight committee.

J Am Coll Cardiol. 79: 1717-1756https://doi.org/10.1016/j.jacc.2022.02.003Tejtel S.K.S. Munoz F.M. Al-Ammouri I. et al.

Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Vaccine. 40: 1499-1511

Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults.

() ()Ferreira V.M. Schulz-Menger J. Holmvang G. et al.

Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations.

J Am Coll Cardiol. 72: 3158-3176Singer M.E. Taub I.B. Kaelber D.C.

Risk of myocarditis from COVID-19 infection in people under age 20: a population-based analysis.

medRxiv. Daniels C.J. Rajpal S. Greenshields J.T. et al.

Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry.

JAMA Cardiol. 6: 1078-1087Moulson N. Petek B.J. Drezner J.A. et al.

SARS-CoV-2 cardiac involvement in young competitive athletes.

Circulation. 144: 256-266Tom Shimabukuro M. MPH M.B.A.

COVID-19 vaccine safety updates advisory committee on immunization practices (ACIP).

() ()Cooper Jr., L.T. Berry G.J. Shabetai R.

Idiopathic giant-cell myocarditis—natural history and treatment.

N Engl J Med. 336: 1860-1866Birnie D.H. Nery P.B. Ha A.C. et al.

Cardiac sarcoidosis.

J Am Coll Cardiol. 68: 411-421Ekström K. Lehtonen J. Nordenswan H.-K. et al.

Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries.

Eur Heart J. 40: 3121-3128Groeneweg J.A. Bhonsale A. James C.A. et al.

Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members.

Circ Cardiovasc Genet. 8: 437-446Cooper Jr., L.T. Čiháková D.

Do genes influence susceptibility to myocarditis?.

American College of Cardiology Foundation, Washington DC: 593-594Corrado D. Link M.S. Calkins H.

Arrhythmogenic right ventricular cardiomyopathy.

N Engl J Med. 376: 61-72Marcus F.I. McKenna W.J. Sherrill D. et al.

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria.

Circulation. 121: 1533-1541Sen-Chowdhry S. Syrris P. Prasad S.K. et al.

Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity.

J Am Coll Cardiol. 52: 2175-2187Ortiz-Genga M.F. Cuenca S. Dal Ferro M. et al.

Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies.

J Am Coll Cardiol. 68: 2440-2451Smith E.D. Lakdawala N.K. Papoutsidakis N. et al.

Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy.

Circulation. 141: 1872-1884Corrado D. Marra M.P. Zorzi A. et al.

Diagnosis of arrhythmogenic cardiomyopathy: the Padua criteria.

Int J Cardiol. 319: 106-114

Fabry's disease.

Lancet. 372: 1427-1435Frustaci A. Verardo R. Grande C. et al.

Immune-Mediated myocarditis in Fabry disease cardiomyopathy.

J Am Heart Assoc. 7: e009052Schultheiss H.-P. Fairweather D. Caforio A.L. et al.

Dilated cardiomyopathy.

Nat Rev Dis primers. 5: 1-19Coronado M.J. Brandt J.E. Kim E. et al.

Testosterone and interleukin-1β increase cardiac remodeling during coxsackievirus B3 myocarditis via serpin A 3n.

Am J Physiology-Heart Circulatory Physiol. 302: H1726-H1736Onyimba J.A. Coronado M.J. Garton A.E. et al.

The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice.

Biol Sex Differences. 2: 1-13Tschöpe C. Ammirati E. Bozkurt B. et al.

Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.

Nat Rev Cardiol. 18: 169-193Navaratnarajah C.K. Pease D.R. Halfmann P.J. et al.

Highly efficient SARS-CoV-2 infection of human cardiomyocytes: spike protein-mediated cell fusion and its inhibition.

J Virol. 95: e01368-21Robinson S.M. Tsueng G. Sin J. et al.

Coxsackievirus B exits the host cell in shed microvesicles displaying autophagosomal markers.

PLoS Pathog. 10: e1004045Gannagé M. Dormann D. Albrecht R. et al.

Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes.

Cell Host & Microbe. 6: 367-380Kim S.-J. Syed G.H. Khan M. et al.

Hepatitis C virus triggers mitochondrial fission and attenuates apoptosis to promote viral persistence.

Proc Natl Acad Sci. 111: 6413-6418Kyei G.B. Dinkins C. Davis A.S. et al.

Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages.

J Cell Biol. 186: 255-268Taylor M.P. Kirkegaard K.

Modification of cellular autophagy protein LC3 by poliovirus.

J Virol. 81: 12543-12553Fiuza-Luces C. Delmiro A. Soares-Miranda L. et al.

Exercise training can induce cardiac autophagy at end-stage chronic conditions: insights from a graft-versus-host-disease mouse model.

Brain Behav Immun. 39: 56-60Fukuta H. Goto T. Wakami K. et al.

Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials.

Heart Fail Rev. 24: 535-547Hosenpud J.D. Campbell S.M. Niles N.R. et al.

Exercise induced augmentation of cellular and humoral autoimmunity associated with increased cardiac dilatation in experimental autoimmune myocarditis.

Cardiovasc Res. 21: 217-222Kiel R. Smith F. Chason J. et al.

Coxsackievirus B3 myocarditis in C3H/HeJ mice: description of an inbred model and the effect of exercise on virulence.

Eur J Epidemiol. 5: 348-350

Interferon and neutralizing antibody in sera of exercised mice with coxsackievirus B-3 myocarditis.

Proc Soc Exp Biol Med. 151: 333-338Tilles J.G. Elson S.H. Shako J.A. et al.

Effects of exercise on coxsackie A9 myocarditis in adult mice.

Proc Soc Exp Biol Med. 117: 777-782Coronado M. Fajardo G. Nguyen K. et al.

Physiological mitochondrial fragmentation is a normal cardiac adaptation to increased energy demand.

Circ Res. 122: 282-295Di Florio D.N. Sin J. Coronado M.J. et al.

Sex differences in inflammation, redox biology, mitochondria and autoimmunity.

Redox Biol. 31: 101482Caforio A.L. Pankuweit S. Arbustini E. et al.

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Eur Heart J. 34: 2636-2648Petek B.J. Moulson N. Baggish A.L. et al.

Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA).

Br J Sports Med. 56: 913-918Martinez M.W. Tucker A.M. Bloom O.J. et al.

Prevalence of inflammatory heart disease among professional athletes with prior COVID-19 infection who received systematic return-to-play cardiac screening.

JAMA Cardiol. 6: 745-752

Myocarditis.

N Engl J Med. 360: 1526-1538Yancy C.W. Jessup M. Bozkurt B. et al.

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Circulation. 128: 1810-1852Corrado D. Zorzi A. Cipriani A. et al.

Evolving diagnostic criteria for arrhythmogenic cardiomyopathy.

J Am Heart Assoc. 10: e021987Tschöpe C. Cooper L.T. Torre-Amione G. et al.

Management of myocarditis-related cardiomyopathy in adults.

Circ Res. 124: 1568-1583Berg J. Kottwitz J. Baltensperger N. et al.

Cardiac magnetic resonance imaging in myocarditis reveals persistent disease activity despite normalization of cardiac enzymes and inflammatory parameters at 3-month follow-up.

Circ Heart Fail. 10: e004262Al-Khatib S.M. Stevenson W.G. Ackerman M.J. et al.

2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society.

J Am Coll Cardiol. 72: e91-e220Kociol R.D. Cooper L.T. Fang J.C. et al.

Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association.

Circulation. 141: e69-e92Maron B.J. Udelson J.E. Bonow R.O. et al.

Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology.

J Am Coll Cardiol. 66: 2362-2371Weidemann F. Niemann M. Störk S. et al.

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.

J Intern Med. 274: 331-341McKinney J. Connelly K.A. Dorian P. et al.

COVID-19–myocarditis and return to play: reflections and recommendations from a Canadian working group.

Can J Cardiol. 37: 1165-1174Patriki D. Baltensperger N. Berg J. et al.

A prospective pilot study to identify a myocarditis cohort who may safely resume sports activities 3 months after diagnosis.

J Cardiovasc Translational Res. 14: 670-673Georgiopoulos G. Figliozzi S. Sanguineti F. et al.

Prognostic impact of late gadolinium enhancement by cardiovascular magnetic resonance in myocarditis: a systematic review and meta-analysis.

Circ Cardiovasc Imaging. 14: e011492